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Abstract 
 
Introduction. The standard treatment for upper urinary tract urothelial cell carcinoma (UUT-UCCs) is radical nephroureterectomy 
with bladder cuff excision. The endoscopic treatment was introduced with promising results in selected cases. The purpose of this 
study was the retrospective analysis of the factors that can influence the prognosis of the patients with UUT-UCCs who underwent 
endoscopic treatment. 
Patients and method. We identified 187 patients who where diagnosed and treated for UUT-UCCs, between 1998 – 2011, in the 
Urology Department of “Sf. Ioan” Clinical Emergency Hospital, Bucharest. The endoscopic treatment was used in 65 cases. The 
indications for endoscopic treatment were imperative (41 cases) or elective (24 cases). The retrograde approach (rigid or flexible) 
was used in 47 cases, while the anterograde approach was preferred in 18 cases.  Tumor ablation was performed using 
electroresection or Nd:YAG laser. The mean follow-up period was 60 months (range between 6 and 120 months). The follow-up 
protocol included computed tomography or intravenous urography, urinary cytology (selected cases), cystoscopy and ureteroscopy. 
The recurrence rates were reviewed by retrospective analysis.  
Results. During follow-up 31 patients (47.6%) presented upper urinary tract recurrence. In 20 cases (30.7%) bladder recurrence was 
present. The median time from diagnosis to first recurrence was of 12.6 months. 18 patients (27.69%) underwent subsequent 
nephroureterectomy. The survival rates without recurrence at 1, 3 and 5 years were 61% (40 patients), 55.3% (36 patients) and 
52.3% (34 patients). The most significant prognostic factors were: history of bladder tumour, tumour location and size, tumour stage 
and grade. The recurrence rate for pyelocaliceal tumours was 53.84% (21 out of 39 cases) and only 45.45% (10 out of 26 cases) for 
ureteral tumours. The recurrence rate for low-grade tumours was 36,36% (16 out of 44 cases) and 71.42% (15 out of 21 cases) for 
high-grade tumours. The tumours over 1.5 cm were associated with a higher recurrence rate compared with tumours below 1.5 cm 
(64.2 versus 43.13%).  
Conclusions. Endoscopic management of UUT-UCCs offers the advantage of preserving of renal function. Laser treatment of 
malignant urothelial lesions in the upper urinary tract should be reserved for a selected patient. The most important prognostic 
factors for UUT-UCCs evolution are tumours location, size and mostly tumour grade. The patients’ compliance is very important for 
detecting recurrences.  
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Abbreviations 
UUT-UCCs - Upper urinary tract urothelial cell carcinomas 
Introduction 
Upper urinary tract urothelial cell carcinomas 
(UUT-UCCs) are rare, representing 5 to 10% from all 
urothelial tumours [1]. The annual estimated incidence is 
1-2 new cases / 100.000 inhabitants. The pyelocaliceal 
location is 2 times more frequent than the uretheral one; 
synchronous bladder tumours are present in 8-13% cases 
[2]. The large majority are transitional carcinomas (90%), 
while only 10% are squamous carcinomas and 1% are 
adenocarcinomas. The upper urinary tract transitional 
carcinomas increase with age in both genders, with a 
maximum in the sixth and seventh decades.  
  The standard treatment is radical 
nephroureterectomy with bladder cuff excision. The 
operation can be performed in classical fashion (two 
incisions - lumbar and iliac) or by endoscopic desinsertion 
of the distal ureter followed by open surgery [3,4,5] (Fig. 
1). The laparoscopic nephroureterectomy, recently 
introduced, has shown promising results [6]. Journal of Medicine and Life Vol. 5, Issue 1, January‐March 2012 
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Nevertheless, the risk of tumour dissemination was not 
totally reduced [7]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Despite all this, with the advancements made in 
fiber optics technology, lasers and smaller caliber 
endoscopic instruments, the first intention conservative 
endoscopic treatment was introduced in UUT-UCCs with 
promising results [8-14]. The ureteroscopic and/or 
percutaneous approach has imperative indications (in 
patients with solitary kidney, bilateral disease or kidney 
failure) [10,15,16] or elective (superficial single small 
tumour, in patients with normal controlateral kidney) 
[8,9,13]. 
The purpose of this study was the retrospective 
analysis of the factors that can influence the prognosis of 
the patients with UUT-UCCs who underwent endoscopic 
treatment. 
 
Patients and methods 
Between 1998 and 2011, a number of 187 patients 
were diagnosed and treated for UUT-UCCs in the Urology 
Department of “Sf. Ioan” Clinical Emergency Hospital 
Bucharest. In 65 cases the endoscopic approach 
(ureteroscopic or percutaneous) was used as first line of 
treatment.  
The indications for endoscopic treatment were 
imperative (41 cases) or elective (24 cases). The 
endoscopic approach was imperative in patients with: 
solitary kidney (17 cases), bilateral disease (4 cases), and 
chronic kidney failure with preoperative serum creatinine 
higher than 2 (9 cases) or other comorbidities (ASA score 
higher or equal to 3) who were not candidates for open 
surgery (11 cases). The other 24 cases (with elective 
indications) had normal contralateral kidney, solitary 
tumours smaller than 2 cm and visually non-invasive, with 
no personal history of urinary tract interventions (Fig. 2). 
All the patients in this last group accepted a thorough 
postoperative follow-up. Patients who could not fulfill 
these criteria or who refused endoscopic treatment 
underwent open nephroureterectomy.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
None of the patients included in this study had 
metastatic disease at the moment of diagnosis. Tumour 
stage and grading were established according to TNM 
Fig.1 Nephroureterectomy (with endoscopic desinsertion) 
for ureteral tumours 
Fig. 2  Ureteral tumour with elective indication for 
endoscopic treatment Journal of Medicine and Life Vol. 5, Issue 1, January‐March 2012 
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[17] and WHO classifications [18]. The preoperative 
hydronephrosis grade was established by abdominal 
ultrasound or computed tomography.  
  When possible, flexible or rigid ureteroscopy (47 
cases) was preferred to the percutaneous endoscopic 
approach (18 cases). The ureteroscopic technique was 
that described by most authors [8,19,20]. Electroresection 
or coagulation with Neodymium: Yttrium-Aluminium-
Garnet (Nd:YAG) laser with 600 or 200μm fibers were 
used (Fig. 3 and Fig. 4). For pyelocaliceal tumours higher 
than 1cm and/or unavailable by ureteroscopy, the 
anterograde percutaneous approach was used, with the 
classical technique [14,19,21]. The anterograde 
percutaneous approach included retrograde renal cavities 
pielography, calix puncture, atraumatic tract dilatation to 
avoid extravasation of the contrast fluid and the usage of 
the Amplatz sheath to reduce the intrarenal pressure. 
Electroresection or Nd:YAG (with power settings between 
20 - 45 W) laser were used. The nephrostomy tube was 
placed for 2-5 days. Two patients received adjuvant 
topical treatment with mitomicine C, and 6 patients 
underwent BCG treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The mean follow-up period was of 60 months 
(range between 6 and 120 months). Patients were 
evaluated at 3 and 6 months by computed tomography or 
intravenous urography, urinary cytology (selected cases) 
and ureteroscopy. In the absence of recurrences, this 
protocol was repeated at 6 months in the first 2 years and 
then yearly. 
The disease free survival rate and the disease 
specific survival rate were analyzed. Recurrence after 
endoscopic treatment was defined as in situ (at tumour 
site) or local (other upper urinary tract location that 
underwent treatment). The recurrence was assessed from 
the date of surgery. The survival without disease was 
defined as the period of time from the time of surgery till 
the first local recurrence (urinary tract urothelial tumour), 
detection of metastasis or end of study. The prognostic 
factors established by univariate analysis were: age, 
gender, smoking history, personal history of bladder 
tumour, grade of hyfronephrosys, tumor location, size, 
stage and grade. 
Results  
The mean age at the moment of diagnosis was of 
67 years (range 42-89). Most patients (49 cases, 75.3%) 
had a smoking history.  About 14 % of patients (9 cases) 
had a personal history of bladder tumour.  
  In 39 cases (60%), the tumour was located in the 
renal pelvis or calices (Fig. 5), while 26 patients had 
ureteral tumours (40%). For the ureteral tumours, 
hydronephrosis was absent in 5 cases (19.23%), 
hydronephrosis was of grade I - II in 18 patients (69.23)%) 
and grade III in 3 patients (11.54%). All the patients with 
grade III hydronephrosis had an imperative indication for 
endoscopic treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Nd:YAG laser coagulation for ureteral tumour 
Fig. 5 Inferior caliceal tumour  Fig. 4 Electroresection for ureteral tumour Journal of Medicine and Life Vol. 5, Issue 1, January‐March 2012 
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47 patients had solitary tumours and 18 patients 
had multiple tumours. All the patients with multiple 
tumours had imperative indications for endoscopic 
surgery. 
  During the follow-up, 31 patients (47.6%) 
developed upper urinary tract recurrence.  In 20 cases 
(30.7%) the bladder recurrence was noted (Fig. 6). The 
median time from the moment of diagnosis to the first 
local recurrence was of 12.6 months. 18 patients 
(27.69%) underwent subsequent nephroureterectomy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The disease free survival rates at 1, 3 and 5 years 
from diagnosis were of 61% (40 patients) , 55.3% (36 
patients) and 52.3% (34 patients). 9 patients from those 
who had recurrence died from TCC. Kidney sparing was 
accomplished in almost 2/3 of cases, while 18 patients 
underwent subsequent nephroureterectomy due to 
disease recurrence.   
  In this study, the tumour location, grade, stage, 
size and the grade of hydronephrosis were the most 
significant prognostic factors. The recurrence rate for 
pyelocaliceal tumours was of 53.84% (21 of 39 cases) 
and just 45.45% (10 of 26 cases) for the ureteral tumours 
(Table 1). 
 
Table 1. The most significant prognostic factors 
Table 1.  
    Recurrence 
Renal pelvis  21 (53.84%)  Location 
Ureter  10 (45.45%) 
Grade  Low grade  16 (36.36%) 
Table 1.  
High grade  15 (71.42%) 
< 1.5 cm  22 (43.13%)  Tumor size 
1.5 - 2 cm  9 (64.2%) 
Overall recurrence  31 (47.69%) 
 
  The recurrence rate for low-grade tumours was 
of 36,36% (16 of 44 cases) and 71.42% (15 of 21 cases) 
for high-grade tumours (Fig. 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regarding the tumour size, it is well known that 
there is a direct connection between size and stage. In 
our study the tumours over 1.5 cm were associated with a 
significant higher recurrence rate (especially local 
recurrence) compared with the tumours below 1.5 cm 
(64.2 versus 43.13%).  
Another prognosis factor was the personal history 
of bladder TCC. 6 out of the 9 patients with bladder TCC 
history had an upper urinary tract recurrence.  
Discussion 
The ureteroscopic and percutaneous approach of 
UUT-UCCs was first described in the mid 1980 [22]. 
Although there a small number of published studies 
regarding the role of the laser treatment in UUT-UCCs, 
their number is growing constantly. Most of them report a 
low progression rate (concerning grade and stage) for the 
low-grade tumours. The disease specific mortality rate for 
low-grade tumours is close to zero in most studies [23]. 
The first studies reported recurrence rates below 15% for 
the cases managed by endoscopic treatment, but with a 
small number of cases and short follow-up periods [24]. 
Fig. 6 Bladder recurrence after UUT-UCCs 
Fig. 7 pT1G1 tumour – no recurrence after 36 months Journal of Medicine and Life Vol. 5, Issue 1, January‐March 2012 
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The recent studies describe local recurrence rates 
between 29 and 88%. These big differences between 
results are explained by the different and irregular designs 
of the studies.  Most authors describe recurrence rates of 
35-45% at upper urinary tract level and 30-36% for the 
bladder [25,26]. The recurrence rate from our study is 
47.69% for the upper urinary tract, a value higher than the 
average rate published in literature, explainable by the 
relatively high number of cases from the study group with 
imperative indication for treatment. 
In general the most important prognostic factors for 
the evolution of UUT-UCCs are the tumour location, grade 
and size.  
After some authors, the location is a less important 
prognostic factor, with small differences regarding the 
recurrence rates (33% for pyelocaliceal location versus 
31% for ureteral tumours) [27]. Other authors believe that 
the pyelocaliceal location, with the bladder TCC history 
present, is the most important prognostic factors for the 
UUT-UCCs [28]. In our study group there are significant 
differences concerning the recurrence rate depending on 
location, this being a significant prognostic factor.  
The tumour size is an important prognostic factor 
and is strongly associated with the risk of recurrence. 
Generally, the endoscopic approach of tumours over 2 cm 
is not indicated, most of them being aggressive tumours, 
high-grade or invasive (T2-3). Also, the tumours between 
1.5 and 2 cm have a worse prognosis than the tumours 
below 1.5 cm, no matter the approach: anterograde or 
retrograde [28,29]. As it was mentioned before, the results 
of this study are confirming the results published by other 
authors, proving the importance of the tumour size for the 
prognosis of UUT-UCCs treated endoscopically.  
The tumour grade is maybe the most important 
prognostic factor, the best results being obtained for the 
low-grade tumours. Thus, the disease specific survival 
rate at 5 years is variable in some studies from 80% for 
low grade tumours to 45% for high-grade, some authors 
questioning the need for nephroureterectomy in patients 
with bilateral functioning kidneys and low-grade tumours 
[9,13,15,28]. The current study proves that the main 
indication for the endoscopic approach of UUT-UCCs is 
represented by the low-grade tumours, with the lowest 
recurrence rate (36% versus 71%).  On the contrary, for 
the high-grade lesions the endoscopic treatment has 
more a palliative intent than a curative one.   
These results underline the necessity for the 
overlook of the upper urinary tract and bladder after 
endoscopic treatment. In fact, the patients who choose 
the endoscopic treatment should be advised from the start 
to expect at least one recurrence. This is the reason why 
the follow-up protocol should include cystoscopy, cytology 
and ureteroscopy at 3 and 6 months in the first year after 
the endoscopic treatment of UUT-UCCs.  
Conclusions 
Endoscopic management of  UUT-UCCs offers the 
advantage of preserving of renal function  and may also 
be used in patients who would not tolerate invasive 
therapies. However, laser treatment of malignant 
urothelial lesions in the upper urinary tract should be 
reserved for a selected patient only. The initial stage and 
grade of the tumor is the key to defining the success rate. 
The patients treated by endoscopic surgery need careful 
surveillance due to frequent recurrences.  
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